COX inhibitors: A patent review (2011 - 2014)

Expert Opinion on Therapeutic Patents

Volumn 25, Issue 12, 2015, Pages 1357-1371

  Consalvi, Sara ^a   Biava, Mariangela ^a   Poce, Giovanna ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

anti cancer agents; anti inflammatory agents; COX; COX inhibitors; NSAIDs

Indexed keywords

BENZOTHIOPHENE DERIVATIVE; BIPHENYL DERIVATIVE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; EPOXIDE HYDROLASE; FATTY ACID; FATTY ACID AMIDASE INHIBITOR; INDOLE DERIVATIVE; MOLECULAR SCAFFOLD; NITROXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRAZOLE DERIVATIVE; SELENIUM; TRIAZOLE DERIVATIVE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2;

ANTIINFLAMMATORY ACTIVITY; DRUG CONJUGATION; DRUG STRUCTURE; DRUG TARGETING; HUMAN; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; NEOPLASM; NONHUMAN; PATENT; REVIEW; ANIMAL; DRUG DESIGN; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; NEOPLASMS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG DESIGN; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INFLAMMATION; NEOPLASMS; PATENTS AS TOPIC;

EID: 84949780684     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2015.1090973     Document Type: Review

References (89)

1. Hawkey C. COX-2 inhibitors. Lancet 1999;353:307-14
2. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl AcadSci 1999;96:272-7
3. Hermanson DJ, Gamble-George JC, Marnett LJ, Patel S. Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation. Trends Pharmacol Sci 2014;35:358-67
4. Vecchio AJ, Malkowski MG. The structural basis of endocannabinoid oxygenation by cyclooxygenase-2. J BiolChem 2011;286:20736-45
5. Patrignani P, Patrono C. Cyclooxygenase inhibitors: From pharmacology to clinical read-outs. Biochim Biophys Acta 2015;1851:422-32.
6. Brune K, Patrignani P. New insights into the use of currently available nonsteroidal anti-inflammatory drugs. J Pain Res 2015;8:105-18.
7. Ganesh T. Prostanoid receptor EP2 as a therapeutic target. J Med Chem 2014;57:4454-65
8. Rouzer CA, Marnett LJ. Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways. Chem Rev 2011;111:5899-921
9. Rizzo MT. Cyclooxygenase-2 in oncogenesis. Clin Chim Acta 2011;412:671-87.
10. Finetti F, Terzuoli E, Bocci E, et al. Pharmacological inhibition of microsomal prostaglandin E synthase-1 suppresses epidermal growth factor receptor-mediated tumor growth and angiogenesis. PLoS One 2012;7:e40576
11. Buchanan FG, Wang D, Bargiacchi F, DuBois RN. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J BiolChem 2003;278:35451-7
12. Dannenberg AJ, Altorki NK, Boyle JO, et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2001;2:544-51
13. Garcia M, Velez R, Romagosa C, et al. Cyclooxygenase-2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice. BJU Int 2014;113:E164-77
14. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: A systematic review of the observational studies of selective and non selective inhibitors of cyclooxygenase 2. JAMA 2006;296:1633-44
15. Consalvi S, Alfonso S, Di Capua A, et al. Synthesis, biological evaluation and docking analysis of a new series of methylsulfonyl and sulfamoylacetamides and ethyl acetates as potent COX-2 inhibitors. Bioorg Med Chem 2015;23:810-20
16. Liu J-Y, Li N, Yang J, et al. Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxibmediated cardiovascular events. Proc Natl AcadSci 2010;107:17017-22
17. Martelli A, Breschi MC, Calderone V. Pharmacodynamic hybrids coupling established cardiovascular mechanisms of action with additional nitric oxide releasing properties. Curr Pharm Des 2009;15:614-36
18. Miller MR, Megson IL. Recent developments in nitric oxide donor drugs. Br J Pharmacol 2007;151:305-21
19. Borhade N, Pathan AR, Halder S, et al. NO-NSAIDs. Part 3: Nitric oxidereleasing prodrugs of non-steroidal antiinflammatory drugs. Chem Pharm Bull (Tokyo) 2012;60:465-81
20. Giordani A, Biava M, Anzini M, et al. 1,5-Diaryl-2-alkylpyrrole-3-substituted nitro esters, selective COX-2 inhibitors and nitricoxide donors. WO2012032479; 2012
21. Biava M, Porretta GC, Poce G, et al. Enlarging the NSAIDs family: ether, ester and acid derivatives of the 1,5-diarylpyrrole scaffold as novel antiinflammatory and analgesic agents. Curr Med Chem 2011;18:1540-54
22. Biava M, Porretta GC, Poce G, et al. Novel ester and acid derivatives of the 1,5-diarylpyrrole scaffold as antiinflammatory and analgesic agents. Synthesis and in vitro and in vivo biological evaluation. J Med Chem 2010;53:723-33
23. Biava M, Porretta GC, Poce G, et al. Synthesis, in vitro, and in vivo biological evaluation and molecular docking simulations of chiral alcohol and ether derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agents. Bioorg Med Chem 2008;16:8072-81
24. Biava M, Porretta GC, Poce G, et al. Cyclooxygenase-2 inhibitors. 1,5-diarylpyrrol-3-acetic esters with enhanced inhibitory activity toward cyclooxygenase-2 and improved cyclooxygenase-2/cyclooxygenase-1 selectivity. J Med Chem 2007;50:5403-11
25. Biava M, Battilocchio C, Poce G, et al. Enhancing the pharmacodynamic profile of a class of selective COX-2 inhibiting nitric oxide donors. Bioorg Med Chem 2014;22:772-86
26. Martelli A, Testai L, Anzini M, et al. The novel anti-inflammatory agent VA694, endowed with both NOreleasing and COX2-selective inhibiting properties, exhibits NO-mediated positive effects on blood pressure, coronary flow and endothelium in an experimental model of hypertension and endothelial dysfunction. Pharmacol Res 2013;78:1-9
27. Anzini M, Di Capua A, Valenti S, et al. Novel analgesic/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as cyclooxygenase-2 inhibiting nitric oxide donors. J Med Chem 2013;56:3191-206
28. Biava M, Battilocchio C, Poce G, et al. Improving the solubility of a new class of antiinflammatory pharmacodynamic hybrids, that release nitric oxide and inhibit cycloxygenase-2 isoenzyme. Eur J Med Chem 2012;58:287-98
29. Biava M, Porretta GC, Poce G, et al. Novel analgesic/anti-inflammatory agents: diarylpyrrole acetic esters endowed with nitric oxide releasing properties. J Med Chem 2011;54:7759-71
30. Martinez E, Talley J, Boehm T. No-releasing guanidine-coxib anti-cancer agents. WO2014012000; 2014
31. Konturek PC, Kania J, Burnat G, Hahn EG. NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin. J Physiol Pharmacol 2006;57(Suppl 12):15-24
32. Jendrossek V. Targeting apoptosis pathways by Celecoxib in cancer. Cancer Lett 2013;332:313-24
33. Ramer R, Walther U, Borchert P, et al. Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib. J Lipid Res 2013;54:3116-29
34. Trnka J, Blaikie FH, Logan A, et al. Antioxidant properties of MitoTEMPOL and its hydroxylamine. Free Radic Res 2009;43:4-12
35. Soule BP, Hyodo F, Matsumoto K-I, et al. The chemistry and biology of nitroxide compounds. Free Radic Biol Med 2007;42:1632-50
36. Samuni A, Goldstein S, Russo A, et al. Kinetics and mechanism of hydroxyl radical and OH-adduct radical reactions with nitroxides and with their hydroxylamines. J Am ChemSoc 2002;124:8719-24
37. Samuni AM, Barenholz Y. Stable nitroxide radicals protect lipid acyl chains from radiation damage. Free Radic Biol Med 1997;22:1165-74
38. Flores-Santana W, Moody T, Chen W, et al. Nitroxide derivatives of nonsteroidal anti-inflammatory drugs exert anti-inflammatory and superoxide dismutase scavenging properties in A459 cells. Br J Pharmacol 2012;165:1058-67
39. Wink DA, Flores-Santana W, King SB, et al. Nitroxide modified non-steroidal anti-inflammatory compounds and uses thereof in the treatment and prevention of diseases or disorders. US2012263650; 2012
40. Hassan TA-FM, Al-Hamad SS, Al-Obaid A-R, Piazza GA. Amide amino acid esters of nonsteroidal antiinflammatory drugs (NSAIDs) as potent inhibitors of colon tumor cell growth. EP2623098; 2013
41. Liggett JL, Zhang X, Eling TE, Baek SJ. Anti-tumor activity of non-steroidal antiinflammatory drugs: cyclooxygenaseindependent targets. Cancer Lett 2014;346:217-24
42. Tinsley HN, Grizzle WE, Abadi A, et al. New NSAID targets and derivatives for colorectal cancer chemoprevention. Recent Results Cancer Res 2013;191:105-20
43. Aboul-Fadl T, Al-Hamad SS, Lee K, et al. Novel non-cyclooxygenase inhibitory derivatives of naproxen for colorectal cancer chemoprevention. Med Chem Res 2014;23:4177-88
44. Sahu S, Panda S, Asiri A, Katritzky A. NSAID conjugates with carnosine and amino acids. Synthesis 2013;45:3369-74
45. Mahfouz NM, Omar FA, Aboul-Fadl T. Cyclic amide derivatives as potential prodrugs II: N-hydroxymethylsuccinimide-/isatin esters of some NSAIDs as prodrugs with an improved therapeutic index. Eur J Med Chem 1999;34:551-62
46. Wallace JL, Reuter B, Cicala C, et al. A diclofenac derivative without ulcerogenic properties. Eur J Pharmacol 1994;257:249-55
47. Tammara VK, Narurkar MM, Crider AM, Khan MA. Morpholinoalkyl ester prodrugs of diclofenac: synthesis, in vitro and in vivo evaluation. J Pharm Sci 1994;83:644-8
48. Calder PC. Omega-3 fatty acids and inflammatory processes. Nutrients 2010;2:355-74
49. Buckley JD, Howe PRC. Long-chain omega-3 polyunsaturated fatty acids may be beneficial for reducing obesity-a review. Nutrients 2010;2:1212-30
50. Shapiro H, Theilla M, Attal-Singer J, Singer P. Effects of polyunsaturated fatty acid consumption in diabetic nephropathy. Nat Rev Nephrol 2011;7:110-21
51. Buckley JD, Howe PRC. Anti-obesity effects of long-chain omega-3 polyunsaturated fatty acids. Obes Rev 2009;10:648-59
52. Shay KP, Moreau RF, Smith EJ, et al. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta 2009;1790:1149-60
53. Salinthone S, Yadav V, Bourdette DN, Carr DW. Lipoic acid: a novel therapeutic approach for multiple sclerosis and other chronic inflammatory diseases of the CNS. Endocr Metab Immune Disord Drug Targets 2008;8:132-42
54. Milne J, Jirousek M, Bemis J, Vu C. Fatty acid COX inhibitor derivatives and their uses. WO2011109681; 2011
55. Robertson GP, Gowda CDR, Desai DH, Amin SG. Anti-cancer compositions and methods. US2014212475; 2014
56. el-Bayoumy K, Upadhyaya P, Chae YH, et al. Chemoprevention of cancer by organoselenium compounds. J Cell Biochem Suppl 1995;22:92-100
57. Desai D, Kaushal N, Gandhi UH, et al. Synthesis and evaluation of the anti-inflammatory properties of selenium-derivatives of celecoxib. Chem Biol Interact 2010;188:446-56
58. Inceoglu B, Jinks SL, Ulu A, et al. Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways. Proc Natl Acad Sci U S A 2008;105:18901-6
59. Spector AA, Norris AW. Action of epoxyeicosatrienoic acids on cellular function. Am J Physiol Cell Physiol 2007;292:C996-1012
60. Hwang SH, Wagner KM, Morisseau C, et al. Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase. J Med Chem 2011;54:3037-50
61. Zhang G, Panigrahy D, Hwang SH, et al. Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis. Proc Natl Acad Sci U S A 2014;111:11127-32
62. Hammock BD, Hwang SH, Wagner KM, et al. Pyrazole inhibitors of COX-2 and sEH. WO2012082647; 2012
63. Piomelli D. The endocannabinoid system: a drug discovery perspective. Curr Opin Investig Drugs 2005;6:672-9
64. Sasso O, Bertorelli R, Bandiera T, et al. Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions. Pharmacol Res 2012;65:553-63
65. Naidu PS, Booker L, Cravatt BF, Lichtman AH. Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception. J Pharmacol Exp Ther 2009;329:48-56
66. Alhouayek M, Muccioli GG. COX-2-derived endocannabinoid metabolites as novel inflammatory mediators. Trends Pharmacol Sci 2014;35:284-92
67. Favia AD, Habrant D, Scarpelli R, et al. Identification and characterization of carprofen as a multitarget fatty acid amide hydrolase/cyclooxygenase inhibitor. J Med Chem 2012;55:8807-26
68. Fowler CJ, Naidu PS, Lichtman A, Onnis V. The case for the development of novel analgesic agents targeting both fatty acid amide hydrolase and either cyclooxygenase or TRPV1. Br J Pharmacol 2009;156:412-19
69. De Vivo M, Scarpelli R, Cavalli A, et al. Multitarget FAAH and COX inhibitors and therapeutical uses thereof. WO2014023643; 2014
70. Fowler CJ, Björklund E, Lichtman AH, et al. Inhibitory properties of ibuprofen and its amide analogues towards the hydrolysis and cyclooxygenation of the endocannabinoid anandamide. J Enzyme Inhib Med Chem 2013;28:172-82
71. Holt S, Paylor B, Boldrup L, et al. Inhibition of fatty acid amide hydrolase, a key endocannabinoid metabolizing enzyme, by analogues of ibuprofen and indomethacin. Eur J Pharmacol 2007;565:26-36
72. Penthala N, Crooks P. Indole compounds for use in treating inflammation and cancer. WO2014105957; 2014
73. Surolia A, Banerjee T, Surolia N, Kapoor N. Benzothiophene carboxamide compounds, composition and applications thereof. US2012016014; 2012
74. Alanazi FK, Radwan AA, Alsarra IA. Triazole compounds as anti-inflammatory agents. EP2527335; 2012
75. Friesen RW, Dubé D, Fortin R, et al. Novel 1,2-diarylcyclobutenes: Selective and orally active cox-2 inhibitors. Bioorg Med Chem Lett 1996;6:2677-82
76. Prasit P, Wang Z, Brideau C, et al. The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2 (5H)-furanone], an orally active cyclooxygenase-2-inhibitor. Bioorg Med Chem Lett 1999;9:1773-8
77. Talley JJ, Brown DL, Carter JS, et al. 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem 2000;43:775-7
78. Praveen Rao PN, Amini M, Li H, et al. Design, synthesis, and biological evaluation of 6-substituted-3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors. J Med Chem 2003;46:4872-82
79. Labanauskas L, Udrenaite E, Gaidelis P, Brukstus A. Synthesis of 5-(2-,3-and 4-methoxyphenyl)-4H-1,2,4-triazole-3-thiol derivatives exhibiting antiinflammatory activity. Farmaco 2004;59:255-9
80. Tozkoparan B, Küpeli E, Yeşilada E, et al. Synthesis and evaluation of analgesic/anti-inflammatory and antimicrobial activities of 3-substituted-1,2,4-triazole-5-thiones. Arzneimittelforschung 2005;55:533-40
81. Scilimati A, Perrone M, Vitale P. Heterocycles and their radiolabeled analogs useful as COX-1 selective inhibitors. WO2014115020; 2014
82. Perrone MG, Vitale P, Malerba P, et al. Diarylheterocycle core ring features effect in selective COX-1 inhibition. ChemMedChem 2012;7:629-41
83. Kelkar SS, Reineke TM. Theranostics: combining imaging and therapy. Bioconjug Chem 2011;22:1879-903
84. Vitale P, Tacconelli S, Perrone MG, et al. Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors. J Med Chem 2013;56:4277-99
85. Perrone MG, Malerba P, Uddin MJ, et al. PET radiotracer [18F]-P6 selectively targeting COX-1 as a novel biomarker in ovarian cancer: preliminary investigation. Eur J Med Chem 2014;80:562-8
86. Daikoku T,Wang D, Tranguch S, et al. Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res 2005;65:3735-44
87. Gupta RA, Tejada LV, Tong BJ, et al. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res 2003;63:906-11
88. Kirkby NS, Lundberg MH, Wright WR, et al. COX-2 protects against atherosclerosis independently of local vascular prostacyclin: identification of COX-2 associated pathways implicate Rgl1 and lymphocyte networks. PLoS ONE 2014;9:e98165
89. García Rodríguez LA, González-Pérez A, Bueno H, Hwa J. NSAID use selectively increases the risk of non-fatal myocardial infarction: a systematic review of randomised trials and observational studies. PLoS One 2011;6:e16780